News | Heart Failure | July 13, 2017

Vest Wearable Monitor May Reduce Heart Failure Readmissions

The SensiVest uses radar technology to detect the exact amount of fluid in the lungs

monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

A heart failure patient wearing the SensiVest remote monitoring system for a two-minute a day assessment. 

William Abraham monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

William Abraham, M.D., monitoring a heart failure patient's chest fluid buildup using the SensiVest remote monitoring system. The daily data points can show if a patient is starting to retain fluids prior to the onset of symptoms.

July 13, 2017 — About 5.7 million adults in the U.S. suffer from heart failure, and because of a dangerous buildup of fluid in their lungs, more than half of those patients end up back in the hospital within six months. But researchers say a high-tech vest that is entering U.S. trials may help doctors monitor a heart patient’s symptoms remotely, which may prevent the need for rehospitalization.

The SMILE Trial (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients study) will look at the efficacy of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel. The system is comprised of a wearable vest containing two embedded sensors, one in front and one behind the patient, and a bedside console. 

“The major cause of readmission for heart failure patients is excess fluid in the lungs,” said William Abraham, M.D., FACC, director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, who is leading a randomized, clinical trial of the vest. “The vest allows us to see when the lungs are trending toward being too wet so a patient’s medication can be adjusted before they even notice any symptoms.”

Watch a VIDEO showing how the vest works and to hear more about it from Abraham.

The vest uses radar technology to “see through” the chest and accurately detect the amount of fluid in the lungs. A patient wears the vest for just 90 seconds a day and the information collected is automatically uploaded to a cloud server. The patient’s cardiologist can review the data to determine if any treatment adjustments need to be made to restore the lungs to healthy fluid levels.

“This technology gives us absolute and actionable data of lung fluid content that we can use to keep patients healthy and out of the hospital,” Abraham said. “The fact that it is completely non-invasive and takes less than two minutes a day to use, allows patients to live a better quality of life with heart failure.”

A study initially conducted in Israel reported that hospital readmission rates were reduced by 87 percent for patients who were part of the study. 

The vest uses the same technology used by the military for things like “seeing through” walls before entering a building or searching through rubble for survivors after a natural disaster.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."

Related Content

 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less
 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System
The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019
November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment
Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
Overlay Init